

# 2018

[1]

2014 [2]

1. APL  
>30%  
Auer
2. M3a M3b M3c
3. t 15 17
4. PML/RAR / WBC  $10 \times 10^9/L$

[3-7]

1.
  - 1 WBC  $10 \times 10^9/L$  PLT
  - 4010  $^9/L$  PLT  $40 \times 10^9/L$   
+ATRA20  $mg \cdot e^{-2} \cdot e^{-1}$
  - CR 0.16  $mg \cdot e^{-1} \cdot e^{-1}$  +ATRA20  $mg \cdot e^{-2} \cdot e^{-1}$
  - CR 1010  $^9/L$
  - 72 IDA 8~12
  - $mg \cdot e^{-2} \cdot e^{-1}$  2 4 6 8 DNR 25~45  $mg \cdot e^{-2} \cdot e^{-1}$
  - 2 4 6 8
  - 2 4~6
  - 2

2.

1		ATRA+	14 d		12~16
	+ ATRA	CR APL			
3	d+Ara-C 100 mg $\times$ <sup>-2</sup>	$\times$ <sup>-1</sup> 5 d, 3			ATRA 20 mg $\times$ <sup>-2</sup>
$\times$ <sup>-1</sup> 14 d	14 d	1		14 d	14 d
14 d	2~3	8	2		+ ATRA CR
APL		0.15 mg $\times$ <sup>-1</sup>	$\times$ <sup>-1</sup> 5 d	4	4 4
	ATRA 45 mg $\times$ <sup>-2</sup>	$\times$ <sup>-1</sup> 14 d	14 d	7	
2		2			
	PCR	2	3		PCR
1	3~6	1		2	6~12
	4				

Hb 80g/L,

PLT 3010 <sup>9</sup>/L

PLT 5010 <sup>9</sup>/L

1.5g/L

1.

2.

1.

2.

3.

4.

5.

[1]

1. 2014 [2]  
CR

5% AML Auer

1.010 <sup>9</sup>/L 10010 <sup>9</sup>/L

2. (PR)  
5%~25% 50% Auer  
5% PR

3. NR

PR

4.

CR 5%  
/

[1] . ( 4 ) [M] : 2018 87-97

[2] 2014 J . 2014 35 5 475-477

[3] Lococo F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.[J]. New England Journal of Medicine, 2013, 369(2):111-121.

[4] O'Donnell M R, Tallman M S, Abboud C N, et al. Acute myeloid leukemia, version 2.2013.[J]. Journal of the National Comprehensive Cancer Network Jncn, 2013,

11(9):1047-55..

- [5] Zhu H H, Qin Y Z, Huang X J. Resistance to arsenic therapy in acute promyelocytic leukemia.[J]. *New England Journal of Medicine*, 2014, 370(19):1864-6.
- [6] Zhu H H, Wu D P, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.[J]. *Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology*, 2013, 31(33):42155-21.
- [7] Efficace F, Mandelli F, Avvisati G, et al. Randomized phase trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. *J Clin Oncol* 2014; 32(30):3406-3412.